Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, open-label study of IMMU-130 administered in 21-day treatment cycles,
once or twice weekly for 2 consecutive weeks followed by one week of rest to patients with
metastatic colorectal cancer who have been previously treated with at least one prior
irinotecan-containing regimen. The study is being done to evaluate whether the study drug is
safe and tolerable at different dose levels with these dosing schedules and to obtain
preliminary information on its efficacy.